|
Welcome to the Nucleic Acid Diagnostics & Therapeutics Summit. This inaugural summit will be held in Boston, MA immediately prior to the annual RNAi World Congress, which will address the latest research in RNAi and microRNA research.
In contrast the DxRx Summit will be attended by investors, corporate management, business leaders, legal & regulatory advisors, clinical trial CROs and others who are interested in the diagnostic and therapeutic applications of DNA, RNAi, microRNA's and antisense technology.
Registered delegates will also be eligible to attend a half-day interactive business tutorial on the market and business landscape for diagnostics and therapeutics based on RNAi and microRNAs hosted by Enal Razvi, PhD.
Register now and save up to $200!
Agenda Topics
- Reviews of Company Pipelines
- Clinical Trial Status of Nucleic Acid-Based Therapeutics
- Patent Status of Nucleic Acid-Based Diagnostics and Therapeutics
- Nucleic Acid Drug Delivery
- microRNAs as Diagnostics and Therapeutic Entities
- Nucleic Acid Biomarkers for Personalized Medicine
- Reimbursement and Regulatory Landscape
- Investor Attitudes to this Sector
- Emerging Company Showcase
|
|
Confirmed Speakers Include:
Dmitry Samarsky, Vice President RXi Pharmaceuticals
Nickolay Ferrari, Director of Pharmacology, Topigen
Patrick Lu, President and CEO Sirnaomics
James Patton, Professor Vanderbilt University
Jörg Vollmer, Managing Director, Coley Pharmaceutical
Elena Bichenkova, Lecturer in Medicinal Chemistry, University of Manchester
Daniel Zurr, CEO Quark Pharmaceuticals
David Brown, Director of Drug Discovery, Mirna Therapeutics
William Marshall, CEO Miragen Therapeutics
Klaus Giese, Chief Scientific Officer, Silence Therapeutics
Johannes Fruehauf, CEO, Cequent Pharma
Nobuyoshi Kosaka, National Cancer Center Research Institute
Lorna Brazell, Partner Bird & Bird
Frank Karlson, CSO, NorChip
Adam Baker, Director of Diagnostic Product Development, Exiqon |
Sponsorship Opportunities
Aaron Woodley, Exhibition Manager
a.woodley@selectbiosciences.com
+44 (0)1787 315129 |